Literature DB >> 12040306

The Cornell-Brown Scale for Quality of Life in dementia.

Rebecca E Ready1, Brian R Ott, Janet Grace, Isabella Fernandez.   

Abstract

Quality of life (QOL) in patients diagnosed with dementia is of critical importance. Reliable and valid measurement of patient QOL is essential to evaluate the effectiveness of treatment interventions and to gain a better understanding of the detrimental impact of dementia on patients' lives. In this study, the psychometric properties of a new scale developed to measure QOL, the Cornell-Brown Scale for Quality of Life, were examined. Data were collected from 50 dementia clinic outpatients with a range of cognitive impairment. Scale ratings were based on a brief, joint interview with caregivers and patients. Findings indicated that the scale demonstrated adequate interrater reliability (intraclass r = 0.90) and internal consistency reliability (Cronbach alpha = 0.81). Criterion validity was indicated by a positive correlation between QOL scores and visual analogue positive mood ratings (Spearman rho = 0.63) and a negative correlation between QOL and dementia severity as measured by Clinical Dementia Ratings (Spearman rho = -0.35). Reliability and validity were not adversely affected by patient cognitive impairment. Thus, preliminary data indicate that the Cornell-Brown Scale for Quality of Life is a brief, easily administered, reliable, and valid measure of QOL.

Entities:  

Mesh:

Year:  2002        PMID: 12040306     DOI: 10.1097/00002093-200204000-00008

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  17 in total

Review 1.  A review of quality of life instruments used in dementia.

Authors:  Teake P Ettema; Rose-Marie Dröes; Jacomine de Lange; Gideon J Mellenbergh; Miel W Ribbe
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

Review 2.  [Nonpharmacological treatments: their influence on quality of life of people with dementia and possible impacts by corresponding instruments. A systematic review of literature].

Authors:  M Weidekamp-Maicher
Journal:  Z Gerontol Geriatr       Date:  2013-02       Impact factor: 1.281

3.  Embedding the perceptions of people with dementia into quantitative research design.

Authors:  Hannah M O'Rourke; Wendy Duggleby; Kimberly D Fraser
Journal:  Qual Life Res       Date:  2015-03-26       Impact factor: 4.147

4.  Management of patients with Alzheimer's disease: pharmacological treatment and quality of life.

Authors:  Enrico Mossello; Elena Ballini
Journal:  Ther Adv Chronic Dis       Date:  2012-07       Impact factor: 5.091

5.  [Quality of life in mild cognitive impairment, patients with different stages of Alzheimer disease and healthy control subjects].

Authors:  Elisabeth M Weiss; Ilona Papousek; Andreas Fink; Theresa Matt; Josef Marksteiner; Eberhard A Deisenhammer
Journal:  Neuropsychiatr       Date:  2012-07-27

6.  Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease.

Authors:  Sagrario Martín-Aragón; Paloma Bermejo-Bescós; Juana Benedí; Emanuela Felici; Pedro Gil; José Manuel Ribera; Angel Ma Villar
Journal:  Neurochem Res       Date:  2008-07-10       Impact factor: 3.996

7.  Are Humor Styles of People With Dementia Linked to Greater Purpose in Life?

Authors:  Wingyun Mak; Silvia Sörensen
Journal:  Gerontologist       Date:  2018-09-14

8.  Development and testing of the Alzheimer's Disease and Related Dementias Mood Scale.

Authors:  Ruth M Tappen; Christine L Williams
Journal:  Nurs Res       Date:  2008 Nov-Dec       Impact factor: 2.381

Review 9.  [Critical observations on measuring quality of life of persons suffering from dementia].

Authors:  H-J Gertz; M Berwig
Journal:  Nervenarzt       Date:  2008-09       Impact factor: 1.214

10.  Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI).

Authors:  Paloma Bermejo-Bescós; Sagrario Martín-Aragón; Karim Jiménez-Aliaga; Juana Benedí; Emanuela Felici; Pedro Gil; José Manuel Ribera; Angel María Villar
Journal:  Neurochem Res       Date:  2013-04-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.